Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
MDAI · NASDAQ · Surgical & Medical Instruments & Apparatus
Spectral AI (MDAI) · oqro.io/stocks/MDAI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Spectral AI was filed in the last 90 days. The latest on record was on May 10, 2024.
Since 2021, Spectral AI insiders reported 6 open-market purchases and 17 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
No open-market sale by an insider of Spectral AI (MDAI) was filed with the SEC in the last 90 days.
No trade in Spectral AI (MDAI) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.04−0.27 (−20.61%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−24.6% (−$0.34) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.38 on Nov 20, 2025 to $1.04 on Nov 20, 2026 (−24.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Surgical & Medical Instruments & Apparatus company based in Dallas, Tx.
Last 12 months
−24.6%
Market value
$42.2M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.19M shares sold short (5.4% of shares outstanding), +1.4% vs the previous count, 23.5 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$19.6M
−33.6% vs the year before
Net income, fiscal 2025
−$7.57M
A loss for the year
Shares outstanding
32.2M
As of Aug 11, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Spectral AI reported 6 open-market purchases and 17 sales since 2021; purchases in 2 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $10K1×1 trade | — |
| 2023 | $15K5×5 trades | — |
| 2021 | — | $2.15M17×17 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
We are an artificial intelligence (“AI”) company focused on predictive medical diagnostics. We operate in one segment. Currently, we are devoting substantially all of our efforts towards research and development of our DeepView® System, an internally developed multi-spectral imaging device that has previously received FDA breakthrough device designation status for an earlier version. Given our receipt of the UKCA mark for burn indication on our DeepView System, we expect to begin commercialization activities in the United Kingdom in 2026. Our DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing “Day One” healing assessments.
And 17 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 25, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 25, 2026, compared with the one filed Mar 31, 2025. Read the filing
The Company is not a party to any material legal proceedings or pending claims. The Company is aware of a material threatened claim that it believes is without merit. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. To our knowledge, there is not any material legal proceeding threatened against any of our officers or directors in their corporate capacity.
Source: SEC EDGAR, Form 10-K filed Mar 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
No Schedule 13D or 13G filing on MDAI over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Revenue
$2.86M
−24.7% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$3.76M
Debt $7.44M, cash $11.2M, at Sep 30, 2026
Backlog
$15.7M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 12, 2026.
Revenue and earnings history, 5 fiscal yearsEarnings dates and the stock's moves
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Against the S&P 500 over the year
Since Nov 19, 2025, MDAI is down 28.3% and the index fund is up 4.1%: 32 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much MDAI moves
Beta 1.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Off-exchange trading: 60.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (7.3% on ATS, 52.7% with other brokers), above its 26-week average of 57.3%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (17.1%), CROSSSTREAM (16.7%), IBKR ATS (10.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.